
Although distinct cancers differ in a panoply of factors, the process of cancer evolution has common steps. The formation of tumour-derived blood vessels is the same regardless of cancer type, as well as the components surrounding them. Interestingly, tumours can benefit, a lot, from the healthy cells present in their little universe. But how?
Cancer is the term used to refer to a pool of diseases that display a common trait: the excessive division of abnormal cells1.
Healthy cells divide only upon previous stimuli and when it is needed. After a number of divisions, different cell mechanisms make sure that the cell is still able to divide without any error or loss of information2. When the cell can no longer properly divide, it enters a state of senescence3 or goes through a process called apoptosis4.
Box1 | Senescence and Apoptosis

However, the abnormal cells that give rise to the different types of cancer, do not follow this procedure. These cells divide when it is not demanded by the organism1, in an uncontrollable way, accumulating errors2 and forming masses of cells beyond the tissue boundaries, with the ability to invade the surrounding tissues and metastasize5.
Box2 | Tumour Microenvironment, Extracellular Matrix and Metastasis

Yet, cancer does not simply rely on selfish, undisciplined and unstable cells11. It is supported by a Tumour Microenvironment (TME)7, composed of a multitude of non-malignant cells8, Extracellular Matrix (ECM)9 and soluble molecules. TME allows tumour growth6,10 and is responsible for the attribution of a major part of the cancer-associated hallmarks8,11 (see Figure 1).

When cancer cells divide, the tumour grows in volume, limiting the access of nutrients and oxygen to the internal part of the mass. Thus, internal cells cannot access enough oxygen or none at all (state of hypoxia)12. Hypoxia is, therefore, a common characteristic of growing tumours, to which cancer cells respond by promoting angiogenesis13, a crucial process for tumour progression, i.e. growth, invasion and metastasis. Angiogenesis is the formation of new blood vessels, from the already existing ones, towards the tumour10. It grants the flow of oxygen and nutrients while creating a road for tumour metastasis14.
To enhance the formation of new blood vessels, different growth factors (promoters) are liberated from various cells. These molecules are perceived at the surface of the already existing blood vessels and act as a stimulus, promoting the division of the endothelial cells that cover the vessels to form new ones8. The most common “promoter” in the angiogenic process is Vascular Endothelial Growth Factor (VEGF), although other growth factors might conduct the same function15,16.
In contrast, when endothelial cells are not supposed to divide, the molecules that are released from other cells are perceived, by receptors at the endothelial membrane, as inhibitors of angiogenesis16.
Hereby, to “switch on” angiogenesis, the balance between inhibitors and promoters of this process has to decline toward the promoters (see figure 2)17.

After successfully “switching on” angiogenesis, Endothelial Cells (EC) separate from stabilizing cells (mostly pericytes and smooth muscle cells) or scaffolds and the degradation of the ECM ensues. ECs invade their surroundings and migrate heading for the tumour, giving rise to tube formation and reorganization across the basement membrane17. These steps result in newly formed vessels, to whom Smooth Muscle Cells (SMC) and pericytes are recruited and attach in order to stabilize the new structures. Once stable, this leads to molecular cross-talk that foster survival signalling and VEGF production to maintain the stimuli6,8.
Throughout the process described above, it is possible to find the engagement of various cell types and components that belong to the tumour microenvironment.
ECM acts as a storage of angiogenesis inhibitors and promoters. The liberation of these factors occurs through the degradation of ECM by proteases (e.g. MMPs), that can be released by tumour or stromal18,19 cells. These factors can promote endothelial survival, proliferation, migration and tube formation6,14.
Box3 | Basement Membrane and Stromal Cells

Tumour cells can recruit progenitor endothelial cells. This type of cells can overexpress VEGF receptors becoming active participants in the angiogenic process16.
Fibroblasts (another cell type present in the tumour microenvironment) synthesize ECM components, can regulate the angiogenic “switch” and contribute to the behaviour of ECs by secreting proteases and growth factors6,10. The actions of fibroblasts in the TME are mostly determined by a paracrine regulation20 that arises from the tumour itself, through the secretion of interleukins, interferons and growth factors21.
Inflammatory components and immune cells are able to produce cytokines and chemokines that can act as mitogens22 for endothelial, epithelial and mesenchymal cells, therefore inducing the proliferation, survival and migration of other TME cell types, new vessels driver cells and tumour cells. In the TME, and working in behalf of tumour progression, we can find myeloid-derived suppressor cells, T lymphocytes, B cells, natural killer cells, plasma cells, monocytes, macrophages, neutrophils and eosinophils. Platelets create a pro-angiogenic environment releasing PDGF (Platelet-Derived Growth Factor) upon interacting with tumour cells23.
Box4 | Paracrine Regulation and Mitogens

As seen (Figure 3), the tumour milieu is complex and dynamic in cell composition and cell communication. Even though different types of tumours can use different strategies to “switch on” angiogenesis17, every tactic involves TME components and they always play an important role.

Without TME collaboration and angiogenesis, most solid tumours could not grow beyond a few millimetres, due to lack of nutrients and oxygen, neither invade nor metastasize; Therefore they would not be threatening to human life6,8,14.
Regarding this statement, many efforts have been done in order to therapeutically target the angiogenic process and the involved parties21,24,25.
Despite no one had called “Eureka” for this, it seems the way to go in order to find an innovative therapy that can handle cancer progression, regardless of tumour type.
References
- What Is Cancer? – National Cancer Institute. Available at: https://www.cancer.gov/about-cancer/understanding/what-is-cancer. (Accessed: 12th July 2018)
- Browner, W. S. et al. The genetics of human longevity. Am. J. Med. 117, 851–860 (2004).
- Campisi, J. & D’Adda Di Fagagna, F. Cellular senescence: When bad things happen to good cells. Nat. Rev. Mol. Cell Biol. 8, 729–740 (2007).
- Renehan, A. G., Booth, C. & Potten, C. S. What is apoptosis, and why is it important? BMJ 322, 1536–8 (2001).
- Definition of metastasize – NCI Dictionary of Cancer Terms – National Cancer Institute. Available at: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/metastasize. (Accessed: 12th July 2018)
- Webby, R. J. & Sandbulte, M. R. Table of contents 1. 4912–4924 (2008).
- Definition of tumor microenvironment – NCI Dictionary of Cancer Terms – National Cancer Institute. Available at: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/tumor-microenvironment. (Accessed: 12th July 2018)
- Mittal, K., Ebos, J. & Rini, B. Angiogenesis and the tumor microenvironment: Vascular endothelial growth factor and beyond. Semin. Oncol. 41, 235–251 (2014).
- Frantz, C., Stewart, K. M. & Weaver, V. M. The extracellular matrix at a glance. J. Cell Sci. 123, 4195–200 (2010).
- Watnick, R. S. The Role of the Tumor Microenvironment in Regulating Angiogenesis The Role of the Tumor Microenvironment in Regulating Angiogenesis. 1–21 (2012). doi:10.1101/cshperspect.a006676
- Hanahan, D. & Weinberg, R. A. Hallmarks of Cancer: The Next Generation. Cell 144, 646–674 (2011).
- Samuel, J. & Franklin, C. in Common Surgical Diseases 391–394 (Springer New York, 2008). doi:10.1007/978-0-387-75246-4_97
- Chouaib, S., Umansky, V. & Kieda, C. The role of hypoxia in shaping the recruitment of proangiogenic and immunosuppressive cells in the tumor microenvironment. Contemp. Oncol. (Poznan, Poland) 22, 7–13 (2018).
- Nogués, L., Benito-Martin, A., Hergueta-Redondo, M. & Peinado, H. The influence of tumour-derived extracellular vesicles on local and distal metastatic dissemination. Mol. Aspects Med. 60, 15–26 (2018).
- Itatani, Y., Kawada, K., Yamamoto, T. & Sakai, Y. Resistance to anti-angiogenic therapy in cancer-alterations to anti-VEGF pathway. Int. J. Mol. Sci. 19, 1–18 (2018).
- Hida, K., Maishi, N., Annan, D. & Hida, Y. Contribution of Tumor Endothelial Cells in Cancer Progression. Int. J. Mol. Sci. 19, 1272 (2018).
- Hanahan, D. & Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353–364 (1996).
- Definition of stromal cell – NCI Dictionary of Cancer Terms – National Cancer Institute. Available at: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/stromal-cell. (Accessed: 12th July 2018)
- Wiseman, B. S. Stromal Effects on Mammary Gland Development and Breast Cancer. Science (80-. ). 296, 1046–1049 (2002).
- Paracrine regulation | definition of paracrine regulation by Medical dictionary. Available at: https://medical-dictionary.thefreedictionary.com/paracrine+regulation. (Accessed: 12th July 2018)
- Sundararajan, V., Sarkar, F. H. & Ramasamy, T. S. The versatile role of exosomes in cancer progression: diagnostic and therapeutic implications. Cell. Oncol. 41, 223–252 (2018).
- Mitogens | definition of Mitogens by Medical dictionary. Available at: https://medical-dictionary.thefreedictionary.com/Mitogens. (Accessed: 12th July 2018)
- Albini, A., Bruno, A., Noonan, D. M. & Mortara, L. Contribution to tumor angiogenesis from innate immune cells within the tumor microenvironment: Implications for immunotherapy. Front. Immunol. 9, (2018).
- Podar, K., Fan, F., Schimming, A. & Jaeger, D. Targeting the tumor microenvironment: Focus on angiogenesis. J. Oncol. 2012, (2012).
- Hameed, S., Bhattarai, P. & Dai, Z. Nanotherapeutic approaches targeting angiogenesis and immune dysfunction in tumor microenvironment. Sci. China Life Sci. 61, 380–391 (2018).






